Tradestie Institutional Equity Comparison Engine

MCHPP vs ALAB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ALAB Overall Edge

ALAB Captures Institutional Edge (4โ€“0 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Astera Labs, Inc. Common Stock (ALAB) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, MCHPP trades at N/M Forward P/E with 21.6% operating margin (+42.2% YoY revenue) versus ALAB at 31.0x Forward P/E and 25.5% operating margin (+153.7% YoY). In options structure, MCHPP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ALAB sits in BREAKDOWN (31st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ALAB
MCHPP N/M vs ALAB 31.0x Fwd P/E
Growth & Margin Winner ALAB
Op Margin 21.6% vs 25.5% ยท YoY +42.2% vs +153.7%
Momentum & Technical Winner ALAB
1Y +0.8% vs +44.1% ยท 52W Pos 14% vs 28%
Options & Structure Winner ALAB
UNCLASSIFIED (N/A IV) vs BREAKDOWN (31st %ile IV)
MCHPP NASDAQ
Microchip Technology Incorporated Depositary Shares Each Representing a 1/20th Interest in a Share of 7.50% Series A Mandatory Convertible Preferred Stock
Semiconductors & Related Devices
$52.64
-3.18% 1D
Market Cap N/A
1M Return -17.41%
1Y Return +0.8%
Forward P/E N/M
Unified AI Score
57.1 / 100 HOLD
Tech 74.0 Fund 61.0 Flow 50.0 Mom 60.0
ALAB NASDAQ
Astera Labs, Inc. Common Stock
Semiconductors & Related Devices
$208.25
-6.12% 1D
Market Cap $39.8B
1M Return -27.14%
1Y Return +44.15%
Forward P/E 31.0x
Unified AI Score
53.4 / 100 HOLD
Tech 45.0 Fund 57.0 Flow 67.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MCHPP +0.8% ALAB +44.15% Spread: +43.35 pp (ALAB Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MCHPP TTM Op. Margin: 21.6% ALAB TTM Op. Margin: 25.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MCHPP vs ALAB. Trailing 12-month operating profitability (MCHPP 21.6% vs ALAB 25.5%) and valuation multiples (MCHPP N/M vs ALAB 31.0x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MCHPP (2) vs ALAB (8)
Institutional Metric MCHPP ALAB Criterion Row Winner
Market Capitalization Scale N/A $39.8B Larger Scale ALAB
Trailing P/E Ratio Valuation N/M 90.0x Lower Multiple ALAB
Forward P/E Ratio Valuation N/M 31.0x Lower Multiple ALAB
Revenue Growth (YoY) Growth +42.2% +153.7% Higher Growth ALAB
Operating Margin (TTM) Profitability 21.6% 25.5% Higher Margin ALAB
Net Profit Margin Profitability 15.0% 29.6% Higher Margin ALAB
Return on Equity (ROE) Capital Efficiency 12.6% 28.2% Higher ROE ALAB
52-Week Range Position Momentum 14% ($47โ€“$88) 28% ($98โ€“$499) Stronger Trend ALAB
Beta / 30D Volatility Risk Regime 2.16ฮฒ ยท 65% Vol 4.24ฮฒ ยท 124% Vol Lower Realized Risk MCHPP
Unified Institutional Score Composite Signal 57.1 / 100 (HOLD) 53.4 / 100 (HOLD) Higher Composite MCHPP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MCHPP vs ALAB Buy Guide
MCHPP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MCHPP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ALAB BREAKDOWN
103d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 31st %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ALAB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MCHPP nor ALAB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.